Indaptus Therapeutics, Inc.INDPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank11
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P11
Within normal range
vs 2Y Ago
-146.8x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -50.61% |
| Q2 2025 | 29.97% |
| Q1 2025 | 4.14% |
| Q4 2024 | 0.93% |
| Q3 2024 | -30.02% |
| Q2 2024 | 1.82% |
| Q1 2024 | 9.65% |
| Q4 2023 | 6.10% |
| Q3 2023 | 0.34% |
| Q2 2023 | -21.76% |
| Q1 2023 | 18.39% |
| Q4 2022 | 11.95% |
| Q3 2022 | -17.78% |
| Q2 2022 | 12.26% |
| Q1 2022 | -7.43% |
| Q4 2021 | -14.85% |
| Q3 2021 | 1841.67% |
| Q2 2021 | 10.68% |
| Q1 2021 | -70.16% |
| Q4 2020 | 111.83% |
| Q3 2020 | -87.94% |
| Q2 2020 | 739.70% |
| Q1 2020 | -87.75% |
| Q4 2019 | -18.51% |
| Q3 2019 | 0.73% |
| Q2 2019 | -2.08% |
| Q1 2019 | 3.46% |
| Q4 2018 | 29.40% |
| Q3 2018 | -25.76% |
| Q2 2018 | 16.43% |
| Q1 2018 | 25.11% |
| Q4 2017 | 7.50% |
| Q3 2017 | 17.86% |
| Q2 2017 | 75.94% |
| Q1 2017 | 0.00% |
| Q4 2015 | -12.46% |
| Q3 2015 | 52.29% |
| Q2 2015 | -66.68% |
| Q1 2015 | 0.00% |